KESTRA MEDICAL TECHNOLOGIES, LTD. Q2 FY26 Results
KMTSQ2 FY26 ResultsAnnounced Dec 11, 2025, 07:00 AM| Metric | Value ($ M) | vs Q1 FY26 |
|---|---|---|
| Revenue | 22.57 | 16.5% |
| Total Income | 22.57 | 16.5% |
| Expenditure | 54.32 | 12.6% |
| PBT | -32.75 | 27.0% |
| Net Profit | -32.79 | 26.9% |
| OPM | — | |
| NPM | — | |
| EPS | -0.64 | 28.0% |
Kestra Medical Technologies Reports Q2 FY26 Revenue Up 53%
04 May 2026 · 4 May, 6:55 am
Summary
Kestra Medical Technologies reported a strong second quarter fiscal 2026, with revenue reaching $22.6 million, a 53% increase year-over-year. The company's gross margin expanded to 50.6%, driven by volume leverage and a higher mix of in-network patients. Kestra increased its FY26 revenue guidance to $91 million, projecting a 52% growth compared to the previous fiscal year. GAAP net loss and comprehensive loss was $32.8 million compared to GAAP net loss and comprehensive loss of $20.6 million in the prior year period.
Key Highlights
- 1
Kestra Medical Technologies generated revenue of $22.6 million in Q2 FY26, representing a 53% increase compared to the prior year period.
- 2
The company's gross margin expanded to 50.6% in Q2 FY26, compared to 39.6% in the prior year period.
- 3
Kestra Medical Technologies increased its FY26 revenue guidance to $91 million, which would represent growth of 52% compared to FY25.
- 4
4,696 prescriptions were written for the ASSURE® system, reflecting a 54% increase compared to the prior year period.
- 5
GAAP operating expenses were $43.2 million, including $1.0 million of non-recurring costs.
Management Comments
Brian Webster
Kestra delivered another strong quarter of financial performance, generating revenue growth of 53% while expanding gross margin to over 50%, an important milestone for the company. We also continued to make progress on several key operational objectives, including growing the commercial organization, announcing compelling primary results from our post-approval study at the American Heart Association annual meeting, and fortifying our balance sheet with an equity offering earlier this month. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers.
Informational and educational content only. Not investment advice.